Friday, January 12, 2024 8:11:28 AM
I am a portfolio shareholder with a well documented and well researched interest in DBMM. That is due diligence. I bought shares after discussion with another supportive shareholder who posts on this chatroom. To infer management is posting is laughable and very pathetic. Passive aggressive misogyny is not a trait to aspire to, but identifies your motivation. I do my homework, that is why the majority of my investments are bluechip . Like the LTIs I am in it to win it . My money, my decision.
One thing I have discovered is Bashers have historically made demands for information or activities which are definitely not required in financial disclosure by regulators. Neither privacy issues, nor competitive positioning are accepted by the same incessant naysayers. The Company has been clear and their position has been accepted and understood by each of the regulators as the Company went through its mitigating circumstances and prevailing— every time. The Company will continue with the advice of professional advisors , all of whom are US public company experts and its strategic blueprint. Not naysayers who do not understand public companies and the regulations.
Read through basher’s archives, outrageous speculation, all the Nevers wrong , yet using the same template. Bashers don’t make the rules, and the Company has said it will only take advice from experts, not bullies.
Likewise, the revisionist history crap as if it matters — it doesn’t. Growing the Company and sustaining geographic expansion is the Company’s message in Updates and Filings.
DBMM and shareholders long and strong, step by step.
Recent DBMM News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 09:32:32 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 11/29/2023 09:31:08 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/17/2023 09:15:45 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM